ArticleJournal of orthopaedic surgery and research2026
Synovial transcriptome analysis reveals ShenTong ZhuYu Tang alleviates osteoarthritis by targeting MMP-9 and immune microenvironment.
Article in Journal of orthopaedic surgery and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Design, Synthesis and Biological Evaluation of Novel Furanocoumarin Derivatives: Validation of Anti-Osteoporotic Efficacy In Vitro and In Vivo.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThis study aimed to elucidate key molecular alterations in the osteoarthritis (OA) synovial microenvironment through transcriptomic analysis and to investigate the multi-target mechanisms of ShenTong ZhuYu Tang (STZYT) using network pharmacology and molecular docking.
methodsWe systematically integrated microarray data from OA synovial tissue available in the Gene Expression Omnibus (GEO) database. An integrated bioinformatics approach, including differential expression analysis, weighted gene co-expression network analysis (WGCNA), immune infiltration profiling, and machine learning, was employed to identify core genes and pathways. Subsequently, a network pharmacology analysis was conducted to construct an herb-compound-target-disease network and elucidate the potential mechanism of action of STZYT. Molecular docking was performed to validate the interaction between key STZYT compounds and matrix metalloproteinase-9 (MMP-9).
resultsA total of 294 differentially expressed genes (DEGs) were identified. Enrichment analysis revealed that these DEGs were significantly involved in inflammatory response and immune regulatory processes, as well as the pathways of osteoclast differentiation, NF-kappa B signaling, and IL-17 signaling. WGCNA and protein-protein interaction network analysis identified 51 hub genes. Subsequently, four machine learning algorithms further refined these to five key diagnostic biomarker candidates (CD4, MMP9, TNFSF11, CX3CR1, and EIF5B). Immune infiltration analysis showed significant infiltration of CD4 + T cells and M2-polarized macrophages. Network pharmacology identified 79 active STZYT compounds and 22 OA-related targets, suggesting the formula acts by inhibiting inflammation, metalloproteinase activity, and fibrosis. Molecular docking studies confirmed that quercetin, luteolin, and baicalein exhibit strong binding affinity to MMP-9.
conclusionsElevated MMP expression, particularly of MMP-9, in synovial tissue is closely associated with OA progression. STZYT may exert therapeutic effects against OA through multi-target mechanisms, including suppressing inflammation, inhibiting metalloproteinases, and preventing synovial fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.